BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/18/2016 3:13:00 PM | Browse: 985 | Download: 1115
Publication Name World Journal of Gastroenterology
Manuscript ID 29003
Country/Territory Sweden
Received
2016-07-25 09:48
Peer-Review Started
2016-07-26 11:46
To Make the First Decision
2016-09-12 17:05
Return for Revision
2016-09-13 08:26
Revised
2016-09-18 22:26
Second Decision
2016-10-14 18:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-10-19 17:31
Articles in Press
2016-10-19 17:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-11-08 17:58
Publish the Manuscript Online
2016-11-18 15:13
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Surgery
Manuscript Type Review
Article Title Immune checkpoint therapy for pancreatic cancer
Manuscript Source Invited Manuscript
All Author List Henrik Johansson, Roland Andersson, Monika Bauden, Sarah Hammes, Stefan Holdenrieder and Daniel Ansari
Funding Agency and Grant Number
Corresponding Author Daniel Ansari, MD, PhD, Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, SE-221 85 Lund, Sweden. daniel.ansari@med.lu.se
Key Words Pancreatic cancer; Immune checkpoint inhibitors; Clinical trials
Core Tip Immunotherapy is a rapidly expanding field within pancreatic cancer research. Here we summarize the effectiveness of immune checkpoint inhibition in the treatment of pancreatic cancer, focusing on the anti-tumor response and toxicity of drugs targeting cytotoxic T lymphocyte antigen 4, programmed cell death 1 and programmed cell death ligand 1. Based on the results from small series it appears that immune checkpoint inhibitors may be safe and effective, but still little published evidence is available to prove or disprove the clinical benefit of these drugs in patients with pancreatic cancer. Several well-designed clinical trials are ongoing and the results from these trials are eagerly awaited.
Publish Date 2016-11-18 15:13
Citation Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016; 22(43): 9457-9476
URL http://www.wjgnet.com/1007-9327/full/v22/i43/9457.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i43.9457
Full Article (PDF) WJG-22-9457.pdf
Full Article (Word) WJG-22-9457.doc
Manuscript File 29003-Review.docx
Answering Reviewers 29003-Answering reviewers.pdf
Audio Core Tip 29003-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 29003-Conflict-of-interest statement.pdf
Copyright License Agreement 29003-Copyright assignment.pdf
Peer-review Report 29003-Peer-review(s).pdf
Scientific Misconduct Check 29003-Scientific misconduct check.pdf
Scientific Editor Work List 29003-Scientific editor work list.pdf